

Assessment of Public Comment

The Board received one written comment on the proposal.

The comment supported the addition of Special Consideration #4, but expressed concerns about five medications included in the formulary: Cabozantinib, Dabrafenib, Trametinib, Vandetanib, and Vismodegiv. The comment expressed concern about why these medications were included but not others from the same class of neoplastic agents, given the cost. Because the proposed changes to the formulary did not change this section to the formulary, no change has been made to the proposal as a result of this comment.

The Board will consider this comment for future versions of the formulary, as the that the Board will continually review and take feedback into consideration.